The Dr. Holhoș network has inaugurated the largest private ophthalmology hospital in Transylvania, following an investment of approximately €6 million.
Romanian patients wait, on average, 460 days to access innovative medicines, even after these therapies have been approved for reimbursement by the National Agency for Medicines and Medical Devices (ANMDM).
7X Partners, a private equity investment company, has acquired a 40% stake in Leventer Medical Group, a centre for dermato-oncology based in Bucharest.
The agreement signifies a joint commitment to enhance healthcare infrastructure in Romania.
ING Bank Romania has financed Medisprof Group, which owns the largest private oncology hospital in western Romania, to expand in the region of Moldova.
Electro-Alfa International, a Romanian electrical equipment manufacturer, has announced plans for an Initial Public Offering (IPO) on the Bucharest Stock Exchange (BVB).
Global life sciences M&A activity increased by 81% in 2025 to $240 billion, driven by Big Pharma's large-scale deals, despite fewer overall transactions. The surge reflects companies prioritising innovations ready for launch as they face widening growth gaps.
Romania's Ministry of Finance will conduct its first public offering of Fidelis government bonds for 2026 between January 16 and 23 on the Bucharest Stock Exchange. This marks the 32nd offering since the Fidelis program resumed in July 2020.
Romania's final electricity consumption fell by 0.7% in the first 11 months of 2025 compared to the same period in 2024, according to data published by the National Institute of Statistics (INS).
Romania has the second-lowest consumer prices in the European Union, with costs 36% below the EU average in 2024, according to new Eurostat data released in December 2025.